Antisense drug developer Lorus Therapeutics said this week that President and CEO Jim Wright has resigned.
According to the company, Wright will continue to be associated with Lorus as a director and special advisor.
Lorus also announced that Aiping Young has been appointed the firm’s new president and CEO.
Young has held a number of positions at Lorus, including vice president of research and development, CTO, and COO. Most recently, he was vice president of research for Lorus subsidiary GeneSense Technologies.